Previous 10 | Next 10 |
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Webinar Scheduled for June 10, 2021 at 4pm Eastern Time / 1pm Pacific Time Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that it plans t...
Recent advances in stem cell technologies, armed with the ability to generate almost any tissue-specific cell types of the body in a dish, human pluripotent stem cells (hPSCs) have drastically moved therapeutic research forward in unprecedented ways. Stem cell-derived cells are increasingly re...
Gainers: Washington Prime (WPG) +99%.Orbital Energy (OEG) +67%.Vertex Energy (VTNR) +28%.LexinFintech (LX) +28%.ENGlobal (ENG) +28%.New Concept Energy (GBR) +26%.Cloudera (CLDR) +24%.Aethlon Medical (AEMD) +24%.Aesthetic Medical International (AIH) +22%.Lineage Cell Therapeutics (LCTX) +...
Shares of Lineage Cell Therapeutics (NYSEMKT: LCTX) were soaring by 19.4% as of 12:01 p.m. EDT on Tuesday. The big gain came after the company announced positive news from a phase 1/2a study evaluating OpRegen in treating dry age-related macular degeneration (AMD). Lineage Cell ...
Gainers: Nuwellis (NUWE) +20%, Aesthetic Medical International (AIH) +20%, Aethlon Medical (AEMD) +19%, Lineage Cell Therapeutics LCTX +18%, Rezolute (RZLT) +17%.Losers: Immunovant IMVT -27%, Shineco (TYHT) -12%, Genetic Technol...
Vertex Energy (VTNR) +28%.Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.Orbsat Corp Common Stock (OSAT) +19%.AMC Entertainment Holdings AMC +16% on raising $230.0 million.Lineage Cell Therapeutics LCTX +14% on updat...
Lineage Cell Therapeutics (LCTX) announces that restoration of retinal tissue was observed in two additional patients enrolled in Company’s Phase 1/2a study of its lead product candidate, OpRegen.OpRegen is an allogeneic retinal pigment epithelium ((RPE)) cell transplant therapy in dev...
Restoration Was Observed in Two Additional Patients in a Phase 1/2a Clinical Study of OpRegen An Earlier and First-Known Clinical Report of Restoration Has Been Maintained for 3 Years Restoration Has Been Observed in Three of Four Patients Who Received OpRegen RPE Ce...
Image source: The Motley Fool. Lineage Cell Therapeutics, Inc. (NYSEMKT: LCTX) Q1 2021 Earnings Call May 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Ca...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...